http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Akers Biosciences Announces Lifting of Temporary Suspension of Trading on the London Stock Exchange
-
Akers Biosciences Signs a Further Independent Sales Representative Organization for Heparin PF4 Rapid Test Covering Additional 12 States
-
Akers Biosciences Signs a Further Independent Sales Representative Organization for Heparin PF4 Rapid Test Covering Additional 12 States
-
Akers Biosciences Announces Q1 2018 Earnings
-
Akers Biosciences Announces Q1 2018 Earnings
-
Akers Biosciences Files Restated Previously Issued Financial Statements for 2017
-
Akers Biosciences Files Restated Previously Issued Financial Statements for 2017
-
Akers Biosciences Further Extends Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
-
Akers Biosciences Further Extends Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
-
Akers Biosciences Requests Temporary Suspension of Trading on London Stock Exchange
-
Akers Biosciences Requests Temporary Suspension of Trading on London Stock Exchange
-
Akers Biosciences Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
-
Akers Biosciences Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
-
Akers Biosciences (AKER) Announces Raymond Akers has Resigned as Director
-
Akers Biosciences (AKER) Withdraws FDA 510(k) Submission for PIFA Chlamydia Rapid Assay Pending Further Evaluation
-
Akers Biosciences Withdraws FDA 510(k) Submission for PIFA Chlamydia Rapid Assay Pending Further Evaluation
-
Akers Biosciences Announces a Change to the Board of Directors
-
Akers Biosciences Withdraws FDA 510(k) Submission for PIFA Chlamydia Rapid Assay Pending Further Evaluation
-
Akers Biosciences Announces a Change to the Board of Directors
-
Akers Biosciences Receives Notice of Delinquent Form 10-Q Filing from Nasdaq
-
Akers Biosciences Receives Notice of Delinquent Form 10-Q Filing from Nasdaq
-
Akers Biosciences (AKER) Announces Expansion of Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
-
Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
-
Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
-
Akers Biosciences (AKER) Reports FY17 Revenue of $3.93M
-
Akers Biosciences Reports Earnings for Fiscal Year 2017
-
Akers Biosciences Reports Earnings for Fiscal Year 2017
-
Akers Biosciences Announces Rescheduled Conference Call to Discuss Fiscal Year 2017 Earnings
-
Akers Biosciences Announces Rescheduled Conference Call to Discuss Fiscal Year 2017 Earnings
-
Akers Biosciences (AKER) Enters US Distribution Agreement with Diagnostica Stago
-
Akers Biosciences Signs US Distribution Agreement with Diagnostica Stago
-
Akers Biosciences Signs US Distribution Agreement with Diagnostica Stago
-
Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings
-
Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings
-
Akers Biosciences Announces Closing of $6,900,000 Public Offering
-
Akers Biosciences Announces Closing of $6,900,000 Public Offering
-
Akers Biosciences (AKER) Prices 15.5M Share Common Offering at $0.15/Sh
-
Akers Biosciences Prices $6,000,000 Public Offering
-
Akers Biosciences Prices $6,000,000 Public Offering
-
Akers Biosciences Secures Further Intellectual Property Protection for Akers Wellness Line
-
Akers Biosciences Secures Further Intellectual Property Protection for Akers Wellness Line
-
Akers Biosciences Announces Q3 2017 Earnings
-
Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer
-
Akers Biosciences Announces Conference Call to Discuss Q3 2017 Earnings
-
Akers Biosciences Hires Medical Device Specialist to Lead US Sales and Distribution
-
Akers Biosciences Announces Q2 2017 Earnings
-
Akers Biosciences Announces Board Changes
-
Akers Biosciences Announces Second Quarter Trading Update
-
Akers Biosciences Announces Q1 2017 Earnings
-
Akers Biosciences Announces Conference Call to Discuss Q1 2017 Earnings

